Market Place
Sourcing Support
BioAge Labs to Present at Upcoming Investor Conferences
21 Nov 2024 //
GLOBENEWSWIRE
BioAge Labs Reports Q3 2024 Financial Results & Business Updates
07 Nov 2024 //
GLOBENEWSWIRE
BioAge Labs Presents Preclinical Azelaprag Data at ObesityWeek 2024
04 Nov 2024 //
GLOBENEWSWIRE
BioAge Labs to Present at Jefferies London Healthcare Conference
24 Oct 2024 //
GLOBENEWSWIRE
BioAge Labs Closes IPO with Full Underwriters’ Option Exercise
01 Oct 2024 //
GLOBENEWSWIRE
BioAge Labs Announces Pricing of Upsized Initial Public Offering
25 Sep 2024 //
GLOBENEWSWIRE
Obesity drug developer BioAge aims up to $640 mln valuation in IPO
25 Sep 2024 //
REUTERS
Weight-loss drug developer BioAge raises $198 mln in U.S. IPO
25 Sep 2024 //
REUTERS
Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
19 Sep 2024 //
REUTERS
Eli Lilly partner BioAge files for US IPO
03 Sep 2024 //
REUTERS
BioAge Appoints Jean-Pierre Garnier As Board Chair
22 Aug 2024 //
BUSINESSWIRE
BioAge Doses First Patient In STRIDES Phase 2 Obesity Trial
29 Jul 2024 //
BUSINESSWIRE
BioAge Labs Presents Preclinical Data for Azelaprag in Obesity
21 Jun 2024 //
BUSINESSWIRE
BioAge Labs Announces Inaugural Scientific Advisory Board
15 May 2024 //
BUSINESSWIRE
Eli Lilly partner BioAge raises $170 mln for obesity treatment
13 Feb 2024 //
REUTERS
GLP-1 enthusiasm pushes BioAge into new age with $170M series D
13 Feb 2024 //
FIERCE BIOTECH
BioAge Announces Plans for Phase 2 of BGE-105 Co-Administered With Tirzepatide
26 Oct 2023 //
BUSINESSWIRE
Lilly, BioAge to test muscle regeneration drug with tirzepatide
26 Oct 2023 //
FIERCE BIOTECH
BioAge Labs Appoints BJ Sullivan as Chief Strategy Officer
22 May 2023 //
BUSINESSWIRE
BioAge Labs to Present on Therapeutics for Brain Aging Targeting NLRP3, Apelin
26 Apr 2023 //
BUSINESSWIRE
BioAge Hosting Webcast to Discuss Phase 1b Data of BGE-105
14 Dec 2022 //
BUSINESSWIRE
BioAge Labs reports positive data from muscle atrophy treatment trial
06 Dec 2022 //
CLINICALTRIALSARENA
BioAge Announces Positive Topline Results for BGE-105 in Phase 1b Trial
05 Dec 2022 //
BUSINESSWIRE
BioAge Labs to Present Data on Novel Brain-Penetrant NLRP3 Inhibitors
13 Oct 2022 //
BUSINESSWIRE
BioAge Partners With Age Labs to Decipher Healthy Using Samples and Data
24 Aug 2022 //
BUSINESSWIRE
BioAge CEO to Lead a Panel Discussion at the BIO 2022 Conference
31 May 2022 //
BUSINESSWIRE
BioAge CBO Peng Leong Appointed Company’s First Head of Brain Aging
23 May 2022 //
BUSINESSWIRE
BioAge Developing a Novel Class of Potent NLRP3 Inhibitors
16 May 2022 //
BUSINESSWIRE
First Cohort Dosed in BioAge`s PIb Trial of the Apelin Receptor Agonist BGE-105
19 Apr 2022 //
BUSINESSWIRE
BioAge’s Oral Drug for Aging Immune System Prevents Death From COVID-19 in Mice
21 Mar 2022 //
BUSINESSWIRE
BioAge Labs to Participate in Truist Symposium, Biotech Investment Conferences
28 Feb 2022 //
BUSINESSWIRE
BioAge appoints Dov Goldstein as CFO and Ann Neale as Chief Development Officer
17 Nov 2021 //
BUSINESSWIRE
BioAge Appoints Rekha Hemrajani and Jason Coloma to its Board of Directors
19 Aug 2021 //
BUSINESSWIRE
BioAge Signs Exclusive Agreement With Amgen To Develop and Commercialize Amgen’s
14 Apr 2021 //
NEUROAMERICA
BioAge begins trial of oral inhibitor to treat Covid-19 patients
23 Mar 2021 //
CLINICALTRIALSARENA
BioAge Initiates Phase 2 Trial of BGE-175 to Treat COVID-19 by Reversing Aging
22 Mar 2021 //
BUSINESSWIRE
BioAge Initiates Ph2 Trial of BGE-175 Treat COVID-19 by Reversing Immune Aging
22 Mar 2021 //
BUSINESSWIRE
BioAge Initiates Phase 2a Trial of BGE-117 in Elderly Patients with Anemia
25 Feb 2021 //
BUSINESSWIRE
BioAge Initiates Ph2a Trial of BGE-117 in Elderly Patients with Anemia
25 Feb 2021 //
BUSINESSWIRE
Shionogi and BioAge conclude a license agreement aimed at treating COVID-19
26 Jan 2021 //
PRESS RELEASE
HitGen and BioAge Announce Research Progress in DNA-Encoded Library Based Drug
05 Apr 2020 //
BUSINESSWIRE
